Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson: Q4 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2 per share. The world's biggest maker of health care products posted revenue of $22.52 billion in the period,
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh
Earnings call transcript: Johnson & Johnson Q3 2024 beats EPS forecast
Johnson & Johnson (NYSE:JNJ) reported its third-quarter 2024 earnings, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $2.04, slightly above the forecasted $2.02. The company's revenue also exceeded projections,
Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
MassDevice12h
Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness
Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Ben Johnson coaching tracker: Latest on Lions offensive coordinator, interview updates, teams interested
Lions offensive coordinator Ben Johnson is one of the most in-demand candidates for vacant head-coaching positions, thanks to ...
MarketBeat on MSN5d
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...
Hold Rating for Johnson & Johnson Amid Modest Growth Outlook and Legal Uncertainties
In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...